Camurus AB (publ) (LON: 0RD1)
London
· Delayed Price · Currency is GBP · Price in SEK | Market Cap | 2.57B |
| Revenue (ttm) | 124.25M |
| Net Income (ttm) | 19.58M |
| Shares Out | n/a |
| EPS (ttm) | 0.33 |
| PE Ratio | 131.26 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84 |
| Average Volume | 16,672 |
| Open | 593.00 |
| Previous Close | 597.50 |
| Day's Range | 574.50 - 593.00 |
| 52-Week Range | 197.70 - 596.00 |
| Beta | 0.96 |
| RSI | 57.38 |
| Earnings Date | Feb 13, 2025 |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical... [Read more]
Financial Performance
In 2023, Camurus AB's revenue was 1.72 billion, an increase of 79.52% compared to the previous year's 956.34 million. Earnings were 431.44 million, an increase of 676.63%.
Financial numbers in SEK Financial StatementsNews
US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugm...
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
LUND, Sweden , June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3...